Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 1/20 | 0.58 |
| ▸ | ATP4B | P51164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314157 | 0.83 | RAB9A (0.60) | ATP4AATP4BALDH1A1KDM4ENPC1 | |
| SCHEMBL6310648 | 0.83 | RAB9A (0.49) | ALDH1A1KDM4EMEN1NPC1LMNA | |
| SCHEMBL6318070 | 0.79 | MAPT (0.63) | ATP4AATP4BALDH1A1KDM4EMEN1 | |
| SCHEMBL10898775 | 0.78 | ATP4A (0.62) | ATP4AATP4BALDH1A1KDM4EMEN1 | |
| SCHEMBL6310643 | 0.77 | ATP4A (0.62) | ATP4AATP4BALDH1A1KDM4ENPC1 | |
| SCHEMBL7239534 | 0.74 | ALDH1A1 (0.55) | ATP4AATP4BALDH1A1KDM4EMEN1 | |
| SCHEMBL823907 | 0.74 | ATP4A (1.00) | ATP4AATP4BNPC1MAPTRAB9A | |
| SCHEMBL6318066 | 0.73 | ATP4A (0.65) | ATP4AATP4BALDH1A1KDM4EMEN1 | |
| SCHEMBL17352070 | 0.72 | — | — | |
| Bromide SCHEMBL825847 | 0.72 | ATP4A (0.97) | ATP4AATP4BNPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143581-A1 | Process for preparation of alkoxybenzamides and thiazolyl isocyanates | MITSUI CHEMICALS, INC. (JP) | 2005-06-30 | — | — | US | disclosed |
| EP-1489073-A1 | PROCESS FORPREPARATION OF ALKOXYBENZAMIDES AND THIAZOLYL ISOCYANATES | MITSUI CHEMICALS, INC. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143581-A1 | Process for preparation of alkoxybenzamides and thiazolyl isocyanates | CBR3, CBR1, IDH1 | ATP4A 1592/4885ATP4B 1690/4885ALDH1A1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.